Introduction
This is a Phase II, prospective, multi-center, randomized, open label, parallel group study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations. A total of 176 patients in Germany will be included in the study. The detection of a germline mutation in BRCA1/2 is a prerequisite for screening for the study.
News
Patient recruitment can begin from October 2024. You are welcome to make a referral to one of our trial centers. We will be happy to inform you of the nearest trial center by e-mail.
The inclusion and exclusion criteria as well as more detailed information on the study design are available on request.
Contact
Jana Roßney
